Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

Rhea-AI Summary

Jazz Pharmaceuticals (Nasdaq: JAZZ) has scheduled its 2025 first quarter financial results announcement for Tuesday, May 6, 2025, after U.S. market close. The company will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss the results and provide business updates.

The global biopharma company, headquartered in Dublin, focuses on developing life-changing medicines for serious diseases, with a portfolio including therapies for sleep disorders, epilepsy, and cancer treatments. Participants are advised to register 15 minutes before the scheduled webcast, which can be accessed through the Investors section of Jazz Pharmaceuticals' website.

DUBLIN, April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2025 first quarter financial results and provide a business and financial update.  

Audio webcast/conference call:
U.S. Dial-In Number: +1 800 715 9871
Ireland Dial-In Number: +353 1800 943 926
Additional global dial-in numbers are available here.
Passcode: 5080203

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. 

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
Jeff Macdonald
Exec Dir, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-first-quarter-financial-results-on-may-6-2025-302434748.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When will Jazz Pharmaceuticals (JAZZ) release Q1 2025 earnings?

Jazz Pharmaceuticals will release its Q1 2025 earnings on Tuesday, May 6, 2025, after the U.S. financial markets close.

How can investors access JAZZ's Q1 2025 earnings call?

Investors can access the earnings call via audio webcast at 4:30 p.m. ET through Jazz's investor website or by dialing in using the provided global numbers with passcode 5080203.

What are the main therapeutic areas for Jazz Pharmaceuticals (JAZZ)?

Jazz Pharmaceuticals focuses on sleep disorders, epilepsy, and cancer treatments, with ongoing R&D in oncology and neuroscience.

Where is Jazz Pharmaceuticals (JAZZ) headquartered?

Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with research, development, and manufacturing facilities across multiple countries.